Drug Profile
SRSS 021
Latest Information Update: 15 Apr 2004
Price :
$50
*
At a glance
- Originator Sirus
- Class Antiemetics
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Nausea and vomiting
Most Recent Events
- 15 Apr 2004 Discontinued - Preclinical for Emesis in United Kingdom (Sublingual)
- 30 Jun 2003 Preclinical trials in Emesis in United Kingdom (Sublingual)